Introduction
Pemphigus vulgaris is treated with medications that suppress the autoimmune process driving the disease, reduce skin and mucosal blistering, and help the damaged epithelium heal. The main treatments are systemic corticosteroids, steroid-sparing immunosuppressive drugs, rituximab, and supportive measures such as wound care and infection control. These approaches work by interrupting the production or action of pathogenic antibodies directed against desmogleins, the adhesion proteins that hold keratinocytes together in the epidermis and mucosa. By reducing antibody-mediated cell separation, treatment lowers blister formation, limits erosion, and restores the barrier function of skin and mucous membranes.
Understanding the Treatment Goals
The central goal of treatment in pemphigus vulgaris is to stop the autoimmune attack on epithelial cell adhesion molecules. In this disease, IgG autoantibodies commonly target desmoglein 3 and sometimes desmoglein 1, proteins found in desmosomes. When these proteins are disrupted, keratinocytes lose cohesion, a process called acantholysis, and fragile blisters and erosions form. Treatment therefore aims to reduce the circulating autoantibodies, suppress the immune cells that produce them, and allow epithelial tissue to reattach and repair.
Clinical goals also include controlling pain, improving oral intake when the mouth is involved, preventing dehydration and infection, and limiting the cumulative toxicity of long-term immunosuppression. Because pemphigus vulgaris can be chronic and relapsing, treatment decisions are often shaped by the need to bring disease activity under control quickly while minimizing exposure to drugs that can cause metabolic, infectious, or organ-specific complications. The balance between disease suppression and adverse effects is a major reason treatment is individualized.
Common Medical Treatments
Systemic corticosteroids are the traditional foundation of treatment. Drugs such as prednisone or prednisolone reduce inflammation and immune activation by altering gene transcription in many immune cells. They decrease cytokine production, limit T-cell activation, and reduce the survival and activity of B cells that generate autoantibodies. In pemphigus vulgaris, this leads to a reduction in the level and functional impact of antibodies against desmogleins. Steroids can improve active blistering relatively quickly, which is why they are often used to gain rapid control of disease.
Because prolonged corticosteroid use can produce substantial toxicity, they are frequently combined with steroid-sparing immunosuppressants. Azathioprine inhibits purine synthesis, which restricts proliferation of activated lymphocytes that depend on rapid DNA replication. Mycophenolate mofetil blocks inosine monophosphate dehydrogenase, a key enzyme in guanine nucleotide synthesis, and therefore selectively impairs lymphocyte expansion. These agents do not directly repair desmosomes, but they reduce the immune system’s capacity to sustain the antibody response responsible for acantholysis. They are used to maintain remission and reduce reliance on corticosteroids.
Rituximab has become a major treatment for pemphigus vulgaris. It is a monoclonal antibody directed against CD20, a surface marker on most mature B cells. By depleting CD20-positive B cells, rituximab reduces the precursor population that differentiates into plasma cells and memory B cells involved in autoantibody production. Since the pathogenic process in pemphigus vulgaris depends on antibody formation, B-cell depletion targets a central step in disease biology rather than only its downstream inflammation. This mechanism explains why rituximab can induce durable remission in many patients and has moved from rescue therapy to first-line use in many treatment strategies.
Intravenous immunoglobulin (IVIG) is another option in selected cases. IVIG consists of pooled IgG from many donors and affects the immune system through several mechanisms. It can modulate Fc receptors, alter complement activity, influence autoantibody catabolism, and interfere with the function of pathogenic antibodies. In pemphigus vulgaris, IVIG helps reduce the biological activity of circulating autoantibodies without broadly suppressing bone marrow function in the same way as some other immunosuppressants. For this reason, it may be used when rapid immune modulation is needed or when other medications are limited by toxicity.
Other immunosuppressive agents such as cyclophosphamide, methotrexate, or dapsone have been used in certain situations, though less commonly than corticosteroids, azathioprine, mycophenolate, or rituximab. Cyclophosphamide interferes with DNA replication and immune-cell proliferation, but its toxicity profile limits routine use. Methotrexate inhibits folate-dependent pathways needed for cell division and can reduce immune activity. Dapsone has anti-inflammatory effects partly related to neutrophil inhibition, though pemphigus vulgaris is primarily antibody mediated, so dapsone is not a core therapy. These agents are chosen when particular clinical circumstances make them more suitable than standard options.
Procedures or Interventions
Although pemphigus vulgaris is treated primarily with medications, certain clinical interventions are used to manage severe disease or complications. Plasma exchange, or plasmapheresis, physically removes circulating plasma containing pathogenic autoantibodies. By lowering antibody concentration in the bloodstream, it can produce a rapid but temporary reduction in blistering. Because the immune system continues to make antibodies, plasma exchange is usually combined with immunosuppressive therapy so that antibody levels do not rebound. It is generally reserved for severe, refractory, or rapidly progressive cases.
Supportive wound-based interventions are also important when erosions are extensive. Nonadherent dressings protect exposed epidermis, reduce mechanical trauma, and create an environment that favors re-epithelialization. When the skin barrier is disrupted, the tissues lose their normal function as a waterproof and antimicrobial surface. Protective wound care helps compensate for this loss while medical therapy reduces the underlying autoimmunity. In some patients, oral lesions require modifications in texture or acidity of foods to minimize mechanical injury to fragile mucosa, though the main effect is indirect: less friction means less trauma to already weakened epithelial adhesion.
Hospitalization may be necessary in severe cases to manage fluid loss, nutrition, electrolyte balance, and secondary infection. These interventions do not alter autoantibody production directly, but they address the physiologic consequences of widespread epithelial breakdown. Because mucosal involvement can impair swallowing and oral intake, enteral or parenteral nutritional support may be used when needed to preserve metabolic stability and tissue repair.
Supportive or Long-Term Management Approaches
Long-term management is aimed at maintaining remission and preventing relapse while reducing cumulative drug toxicity. This usually involves tapering corticosteroids after disease control is achieved and using maintenance immunosuppression when necessary. The rationale is biological: once pathogenic antibody production is suppressed and new blister formation has stopped, the body can restore epithelial adhesion and barrier integrity, but the autoimmune tendency may persist. Ongoing treatment helps prevent renewed B-cell activation and antibody resurgence.
Regular monitoring of blood counts, liver function, kidney function, glucose, and blood pressure is often part of long-term care because many therapies alter immune function or affect organ systems. These checks help detect treatment-related physiological changes before they become clinically significant. For example, azathioprine can suppress bone marrow function, mycophenolate can lower leukocyte counts, and corticosteroids can cause hyperglycemia, fluid retention, osteoporosis, and muscle catabolism. Monitoring is therefore not merely administrative; it reflects how these drugs influence fundamental body systems.
Supportive skin and oral care also contribute to disease control by reducing secondary complications. Maintaining intact surrounding tissue decreases bacterial entry through erosions, and minimizing trauma reduces the chance that fragile desmosome-deficient epithelium will separate again. Since infection and inflammation can amplify tissue injury, supportive measures help preserve the healing process while the immune disease is brought under control. In chronic disease, the overall strategy is often to achieve the lowest effective immunosuppressive burden that maintains remission.
Factors That Influence Treatment Choices
Treatment selection depends heavily on disease severity. Limited mucosal disease may be managed differently from widespread cutaneous and mucosal involvement because the latter reflects a broader burden of autoantibody activity and a higher risk of fluid loss, infection, and nutritional compromise. More aggressive disease often requires faster-acting therapy, such as higher-dose corticosteroids or rituximab, whereas milder or more stable disease may be controlled with lower-intensity regimens or maintenance therapy after induction.
The stage of the disease also matters. In an active flare, the priority is rapid suppression of autoantibody effects and inflammation. In remission, the focus shifts toward preventing recurrence and minimizing long-term adverse effects. The biology of pemphigus vulgaris changes over time: early treatment may need to block acute blister formation, while later treatment may aim to keep autoreactive B cells from re-expanding.
Age, pregnancy status, frailty, and coexisting medical conditions influence which drugs are acceptable. Corticosteroids can worsen diabetes, osteoporosis, hypertension, and mood disorders. Some immunosuppressants carry infection risk or may be unsuitable in liver disease, kidney disease, or cytopenias. Rituximab may be preferred when steroid toxicity is a major concern, while other agents may be avoided in patients with prior adverse reactions or higher baseline risk. Previous response to treatment is also important. A patient who relapses on steroid tapering may need a stronger steroid-sparing agent, whereas someone with an excellent response to one drug may remain on that regimen longer.
Potential Risks or Limitations of Treatment
The principal limitation of pemphigus vulgaris treatment is that most therapies suppress the immune response rather than directly correcting the autoimmune predisposition. As a result, relapse can occur when treatment is reduced or stopped. Because the disease mechanism involves long-lived immune memory and persistent autoantibody production, durable control may require prolonged therapy and careful follow-up.
Corticosteroids are effective but can cause metabolic and structural complications. Their biologic effects include decreased collagen synthesis, altered glucose metabolism, immune suppression, and bone loss. These changes explain why prolonged use can lead to osteoporosis, muscle weakness, infection risk, cataracts, and adrenal suppression. Steroid-sparing agents reduce the steroid burden but add their own risks. Azathioprine and mycophenolate can suppress bone marrow and increase susceptibility to infection. Cyclophosphamide can cause infertility, hemorrhagic cystitis, and malignancy risk through DNA damage. Rituximab can predispose to infection by depleting B cells needed for humoral immunity, and infusion reactions may occur during administration.
Procedural approaches also have limitations. Plasma exchange removes antibodies quickly, but because it does not stop their production, the effect is transient unless combined with immunosuppressive therapy. Supportive wound care helps preserve tissue function but cannot prevent new lesions if the autoimmune process remains active. These limitations reflect the underlying biology of pemphigus vulgaris: the disease is driven by a self-sustaining immune response that usually requires both rapid control and longer-term immune modulation.
Conclusion
Pemphigus vulgaris is treated through a combination of immune suppression, targeted B-cell depletion, antibody reduction strategies, and supportive care. Systemic corticosteroids reduce acute inflammatory activity, steroid-sparing agents lower the production of autoreactive lymphocytes, and rituximab directly depletes CD20-positive B cells that generate pathogenic antibodies. In selected severe cases, plasma exchange removes circulating antibodies more rapidly. Supportive care protects damaged skin and mucosa, prevents complications, and allows tissue repair.
These treatments are used because the disorder is fundamentally an autoimmune failure of epithelial adhesion. By reducing antibodies against desmogleins and limiting the immune processes that sustain them, treatment addresses both the symptoms and the underlying mechanism of blister formation. The overall objective is to restore barrier integrity, maintain remission, and reduce the long-term consequences of chronic immune suppression.